Article
UPDATED: Mirati plots a march to the FDA for its KRAS G12C drug, breathing down Amgen's neck with
Rating:
0.0
Views:
271
Likes:
1
Library:
1
Mirati Therapeutics $MRTX took another closely-watched step toward a now clearly defined goal to file for an approval for its KRAS G12C cancer drug adagrasib (MRTX849), scoring a higher response rate than the last readout from the class-leading rival at Amgen but still leaving
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value